WestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48

Benzinga Newsdesk www.benzinga.com Positive 59.3%

Neg 0% Neu 0% Pos 59.3%

WestPark Capital initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $48.